122 related articles for article (PubMed ID: 36379207)
1. CD16
Liu X; Lu Y; Huang J; Xing Y; Dai H; Zhu L; Li S; Feng J; Zhou B; Li J; Xia Q; Li J; Huang M; Gu Y; Su S
Cancer Cell; 2022 Nov; 40(11):1341-1357.e13. PubMed ID: 36379207
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated cortactin recruits Vav2 guanine nucleotide exchange factor to activate Rac3 and promote invadopodial function in invasive breast cancer cells.
Rosenberg BJ; Gil-Henn H; Mader CC; Halo T; Yin T; Condeelis J; Machida K; Wu YI; Koleske AJ
Mol Biol Cell; 2017 May; 28(10):1347-1360. PubMed ID: 28356423
[TBL] [Abstract][Full Text] [Related]
3. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
4. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
5. Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation.
Shi Y; Fan X; Meng W; Deng H; Zhang N; An Z
Breast Cancer Res; 2014 Apr; 16(2):R33. PubMed ID: 24693969
[TBL] [Abstract][Full Text] [Related]
6. Role of Fcγ receptors in HER2-targeted breast cancer therapy.
Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer.
Luque M; Sanz-Álvarez M; Santamaría A; Zazo S; Cristóbal I; de la Fuente L; Mínguez P; Eroles P; Rovira A; Albanell J; Madoz-Gúrpide J; Rojo F
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948097
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.
Szöőr Á; Tóth G; Zsebik B; Szabó V; Eshhar Z; Abken H; Vereb G
Cancer Lett; 2020 Aug; 484():1-8. PubMed ID: 32289441
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth.
Bourguignon LY; Zhu H; Zhou B; Diedrich F; Singleton PA; Hung MC
J Biol Chem; 2001 Dec; 276(52):48679-92. PubMed ID: 11606575
[TBL] [Abstract][Full Text] [Related]
11. Vav2 activates Rac1, Cdc42, and RhoA downstream from growth factor receptors but not beta1 integrins.
Liu BP; Burridge K
Mol Cell Biol; 2000 Oct; 20(19):7160-9. PubMed ID: 10982832
[TBL] [Abstract][Full Text] [Related]
12. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.
Zheng G; Guo Z; Li W; Xi W; Zuo B; Zhang R; Wen W; Yang AG; Jia L
Signal Transduct Target Ther; 2021 Jun; 6(1):236. PubMed ID: 34158475
[TBL] [Abstract][Full Text] [Related]
13. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
14. The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells.
Citterio C; Menacho-Márquez M; García-Escudero R; Larive RM; Barreiro O; Sánchez-Madrid F; Paramio JM; Bustelo XR
Sci Signal; 2012 Oct; 5(244):ra71. PubMed ID: 23033540
[TBL] [Abstract][Full Text] [Related]
15. TGFβ-induced early activation of the small GTPase RhoA is Smad2/3-independent and involves Src and the guanine nucleotide exchange factor Vav2.
Papadimitriou E; Kardassis D; Moustakas A; Stournaras C
Cell Physiol Biochem; 2011; 28(2):229-38. PubMed ID: 21865730
[TBL] [Abstract][Full Text] [Related]
16. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis.
Hunter SG; Zhuang G; Brantley-Sieders D; Swat W; Cowan CW; Chen J
Mol Cell Biol; 2006 Jul; 26(13):4830-42. PubMed ID: 16782872
[TBL] [Abstract][Full Text] [Related]
17. Paxillin kinase linker (PKL) regulates Vav2 signaling during cell spreading and migration.
Jones MC; Machida K; Mayer BJ; Turner CE
Mol Biol Cell; 2013 Jun; 24(12):1882-94. PubMed ID: 23615439
[TBL] [Abstract][Full Text] [Related]
18. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
19. Contribution of guanine nucleotide exchange factor Vav2 to hyperhomocysteinemic glomerulosclerosis in rats.
Yi F; Xia M; Li N; Zhang C; Tang L; Li PL
Hypertension; 2009 Jan; 53(1):90-6. PubMed ID: 19029489
[TBL] [Abstract][Full Text] [Related]
20. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
